Report Scope:
This report is a comprehensive study of the global artificial organs market. It describes the artificial organs market, segmented by product type and region. Based on product type, the market is segmented into artificial hearts, artificial kidneys, artificial lungs, artificial pancreases, and cochlear implants. The market is segmented by region into North America, Latin America, Europe, Asia-Pacific, and the Rest of the World (RoW).

This report examines the factors driving growth in the artificial organ market, and it reviews major players, established companies, and new entrants.

This report, however, does not cover artificial limbs, artificial eyes, artificial intestines, artificial skin, or artificial blood vessels.

Report Includes:

  • 28 data tables and 14 additional tables
  • An overview of the global artificial organs market
  • Analyses of global market trends, with data from 2020 to 2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028
  • Discussion about the benefits of using artificial organs over traditional organs in transplantation surgeries, and increase in development of new types of artificial organs as driving factors to the market
  • Identification of challenges and discussion on how to overcome from those to reach its commercialization potential
  • Insights into R&D investments, government growth-promoting policies, rules, and regulations
  • Information on recent mergers, acquisitions, collaborations, agreements, partnerships, product launches, and expansions in the market and a relevant patent analysis
  • Detailed company profiles of major players in the market, including Abbott, Getinge AB, LivaNova, Nipro Corp. and Sonova